Literature DB >> 25327979

The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.

Laura S van Dam1, Verena M de Zwart1, Friederike A G Meyer-Wentrup1.   

Abstract

Programmed cell death-1 (PD-1) and its ligands, PD-L1 and PD-L2 maintain self-tolerance and modulate physiological immune responses. Recently, targeting the PD-1/PD-L1 pathway with blocking antibodies has emerged as a potentially promising approach to treat advanced cancers in adult patients. Since tumor PD-L1 expression is currently considered the most important predictive biomarker for successful checkpoint blockade, we summarize expression data for the most common tumors of childhood. Additionally, we give an introduction into PD-1 function in the immune system to then focus on PD-1 mediated tumor immune escape. Pediatr Blood Cancer 2015;62:190-197.
© 2014 Wiley Periodicals, Inc. © 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  PD-1/PD-L1; cancer immunotherapy; immune checkpoint blockade; pediatric cancer

Mesh:

Substances:

Year:  2014        PMID: 25327979     DOI: 10.1002/pbc.25284

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  14 in total

Review 1.  Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.

Authors:  Jeong A Park; Nai-Kong V Cheung
Journal:  Cancer Treat Rev       Date:  2017-06-01       Impact factor: 12.111

2.  PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO.

Authors:  Nikolai Siebert; Maxi Zumpe; Madlen Jüttner; Sascha Troschke-Meurer; Holger N Lode
Journal:  Oncoimmunology       Date:  2017-07-05       Impact factor: 8.110

Review 3.  Advances in the Management of Pediatric Sarcomas.

Authors:  Fiorela N Hernandez Tejada; Alejandro Zamudio; Mario L Marques-Piubelli; Branko Cuglievan; Douglas Harrison
Journal:  Curr Oncol Rep       Date:  2020-11-16       Impact factor: 5.075

Review 4.  Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines.

Authors:  Theodore S Nowicki; Jennifer L Anderson; Noah Federman
Journal:  Pediatr Res       Date:  2015-11-23       Impact factor: 3.756

5.  Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.

Authors:  Kara L Davis; Elizabeth Fox; Melinda S Merchant; Joel M Reid; Rachel A Kudgus; Xiaowei Liu; Charles G Minard; Stephan Voss; Stacey L Berg; Brenda J Weigel; Crystal L Mackall
Journal:  Lancet Oncol       Date:  2020-03-17       Impact factor: 41.316

Review 6.  PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective.

Authors:  Palanisamy Nallasamy; Srinivas Chava; Sumit S Verma; Shruti Mishra; Santhi Gorantla; Don W Coulter; Siddappa N Byrareddy; Surinder K Batra; Subash C Gupta; Kishore B Challagundla
Journal:  Semin Cancer Biol       Date:  2017-11-28       Impact factor: 15.707

Review 7.  Immune Checkpoint Inhibitors in Pediatric Solid Tumors: Status in 2018.

Authors:  Tanvir F Kabir; Aman Chauhan; Lowell Anthony; Gerhard C Hildebrandt
Journal:  Ochsner J       Date:  2018

Review 8.  Immune Checkpoint in Glioblastoma: Promising and Challenging.

Authors:  Jing Huang; Fangkun Liu; Zhixiong Liu; Hui Tang; Haishan Wu; Qianni Gong; Jindong Chen
Journal:  Front Pharmacol       Date:  2017-05-09       Impact factor: 5.810

9.  Programmed Death Ligand 1 Expression and Related Markers in Pleuropulmonary Blastoma.

Authors:  Zahra Alipour; Kris Ann P Schultz; Ling Chen; Anne K Harris; Ivan A Gonzalez; John Pfeifer; D Ashley Hill; Mai He; Louis P Dehner
Journal:  Pediatr Dev Pathol       Date:  2021-07-15

10.  Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers.

Authors:  Takahiro Aoki; Moeko Hino; Katsuyoshi Koh; Masashi Kyushiki; Hiroshi Kishimoto; Yuki Arakawa; Ryoji Hanada; Hiroshi Kawashima; Jun Kurihara; Naoki Shimojo; Shinichiro Motohashi
Journal:  Pediatr Blood Cancer       Date:  2016-05-02       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.